{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:12:25Z","timestamp":1789737145701,"version":"4.0.1"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004702","name":"Universit\u00e0 degli Studi di Genova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004702","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose of Review<\/jats:title><jats:p>Large vessel vasculitides (LVVs) are inflammatory conditions of the wall of large-sized arteries, mainly represented by giant cell arteritis (GCA) and Takayasu arteritis (TA). The inflammatory process within the vessel wall can lead to serious consequences such as development of aneurysms, strokes and blindness; therefore, early diagnosis and follow-up of LVV are fundamental. However, the arterial wall is poorly accessible and blood biomarkers are intended to help physicians not only in disease diagnosis but also in monitoring and defining the prognosis of these conditions, thus assisting therapeutic decisions and favouring personalised management. The field is the object of intense research as the identification of reliable biomarkers is likely to shed light on the mechanisms of disease progression and arterial remodelling. In this review, we will discuss the role of blood biomarkers in LVVs in the light of the latest evidence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent Findings<\/jats:title><jats:p>In clinical practice, the most widely performed laboratory investigations are the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). However, these indices may be within normal limits during disease relapse and they are not reliable in patients receiving interleukin-6 (IL-6) receptor inhibitors. New biomarkers struggle to gain traction in clinical practice and no molecule with good accuracy has been identified to date. IL-6, a pro-inflammatory cytokine that drives CRP synthesis and increases the ESR, is one of the most promising biomarkers in the field. IL-6 analysis is increasingly performed, and serum levels are more sensitive than ESR for active GCA and might reflect persistent inflammation with high risk of relapse in patients on IL-6 receptor inhibitors. A future with biomarkers that reflect different disease features is an important aspiration. Accordingly, intense effort is being made to identify IL-6-independent inflammatory biomarkers, such as S100 proteins, pentraxin-3 and osteopontin. Moreover, metalloproteinases such as MMP2\/9 and angiogenic modulators such as VEGF, YLK-40 and angiopoietins are being studied as markers of arterial remodelling. Lastly, biomarkers indicating organ damage may guide prognostic stratification as well as emergency therapeutic decisions: the most promising biomarkers so far identified are NT-proBNP, which reflects myocardial strain; pentraxin-3, which has been associated with recent optic nerve ischemia; and endothelin-1, which is associated with ischaemic complications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>Currently, the use of these molecules in clinical practice is limited because of their restricted availability, lack of sufficient studies supporting their validity and associated costs. Further evidence is required to better interpret their biological and clinical value.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s11926-021-00980-5","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T10:58:16Z","timestamp":1613041096000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Blood Biomarkers for Monitoring and Prognosis of Large Vessel Vasculitides"],"prefix":"10.1007","volume":"23","author":[{"given":"Enrico","family":"Tombetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvis","family":"Hysa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin C.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A.","family":"Cimmino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6384-6458","authenticated-orcid":false,"given":"Dario","family":"Camellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,10]]},"reference":[{"key":"980_CR1","doi-asserted-by":"crossref","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1\u201311.","DOI":"10.1002\/art.37715"},{"key":"980_CR2","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/nrrheum.2010.82","volume":"6","author":"JC Mason","year":"2010","unstructured":"Mason JC. Takayasu arteritis--advances in diagnosis and management. Nat Rev Rheumatol. 2010;6:406\u201315.","journal-title":"Nat Rev Rheumatol"},{"key":"980_CR3","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/rheumatology\/key040","volume":"58","author":"E Tombetti","year":"2019","unstructured":"Tombetti E, Mason JC. Takayasu arteritis: advanced understanding is leading to new horizons. Rheumatology. 2019;58:206\u201319.","journal-title":"Rheumatology."},{"key":"980_CR4","doi-asserted-by":"publisher","first-page":"919","DOI":"10.7326\/0003-4819-120-11-199406010-00004","volume":"120","author":"GS Kerr","year":"1994","unstructured":"Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. Ann Intern Med. 1994;120:919\u201329.","journal-title":"Ann Intern Med"},{"key":"980_CR5","doi-asserted-by":"crossref","unstructured":"Crowson CS, Matteson EL. Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015. Semin Arthritis Rheum. 2017;47:253\u20136. A recent and thorough cohort study on the incidence and prevalence of GCA and PMR.","DOI":"10.1016\/j.semarthrit.2017.04.001"},{"key":"980_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11926-014-0480-1","volume":"17","author":"MA Gonz\u00e1lez-Gay","year":"2015","unstructured":"Gonz\u00e1lez-Gay MA, Pina T. Giant cell arteritis and polymyalgia rheumatica: an update. Curr Rheumatol Rep. 2015;17:6.","journal-title":"Curr Rheumatol Rep"},{"key":"980_CR7","doi-asserted-by":"crossref","unstructured":"Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology (Oxford). 2017;56:506\u201315. A thought-provoking review on the multifaceted nature of GCA and PMR.","DOI":"10.1093\/rheumatology\/kew273"},{"key":"980_CR8","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s40266-019-00705-5","volume":"36","author":"D Camellino","year":"2019","unstructured":"Camellino D, Giusti A, Girasole G, Bianchi G, Dejaco C. Pathogenesis, diagnosis and management of polymyalgia rheumatica. Drugs Aging. 2019;36:1015\u201326.","journal-title":"Drugs Aging"},{"key":"980_CR9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0140-6736(08)61077-6","volume":"372","author":"C Salvarani","year":"2008","unstructured":"Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008;372:234\u201345.","journal-title":"Lancet."},{"key":"980_CR10","doi-asserted-by":"crossref","unstructured":"Kermani TA, Schmidt J, Crowson CS, Ytterberg SR, Hunder GG, Matteson EL, et al. Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum. 2012;41:866\u201371.","DOI":"10.1016\/j.semarthrit.2011.10.005"},{"key":"980_CR11","doi-asserted-by":"crossref","unstructured":"Cantini F, Salvarani C, Olivieri I, Macchioni L, Ranzi A, Niccoli L, et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum. 2000;30:17\u201324.","DOI":"10.1053\/sarh.2000.8366"},{"key":"980_CR12","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2013.161","volume":"9","author":"CM Weyand","year":"2013","unstructured":"Weyand CM, Goronzy JJ. Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol. 2013;9:731\u201340.","journal-title":"Nat Rev Rheumatol"},{"key":"980_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1056\/NEJMcp1214825","volume":"371","author":"CM Weyand","year":"2014","unstructured":"Weyand CM, Goronzy JJJ. Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371:50\u20137.","journal-title":"N Engl J Med"},{"key":"980_CR14","first-page":"55","volume":"9","author":"A Laria","year":"2017","unstructured":"Laria A, Lurati A, Scarpellini M. Color duplex ultrasonography findings of temporal arteries in a case of giant cell arteritis: role in diagnosis and follow-up. Open access Rheumatol Res Rev. 2017;9:55\u20139.","journal-title":"Open access Rheumatol Res Rev"},{"key":"980_CR15","doi-asserted-by":"crossref","unstructured":"Prieto-Gonz\u00e1lez S, Esp\u00edgol-Frigol\u00e9 G, Garc\u00eda-Mart\u00ednez A, Alba MA, Tavera-Bahillo I, Hern\u00e1ndez-Rodr\u00edguez J, et al. The expanding role of imaging in systemic vasculitis. Rheum Dis Clin N Am. 2016;42:733\u201351.","DOI":"10.1016\/j.rdc.2016.07.009"},{"key":"980_CR16","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.1016\/j.lpm.2017.03.022","volume":"46","author":"E Tombetti","year":"2017","unstructured":"Tombetti E, Mason JC. Application of imaging techniques for Takayasu arteritis. Presse Med. 2017;46:e215\u201323.","journal-title":"Presse Med"},{"key":"980_CR17","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.4049\/jimmunol.160.11.5294","volume":"160","author":"AJ Szalai","year":"1998","unstructured":"Szalai AJ, van Ginkel FW, Dalrymple SA, Murray R, McGhee JR, Volanakis JE. Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice. J Immunol. 1998;160:5294\u20139.","journal-title":"J Immunol"},{"key":"980_CR18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrrheum.2017.83","volume":"13","author":"S Rose-John","year":"2017","unstructured":"Rose-John S, Winthrop K, Calabrese L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat Rev Rheumatol. 2017;13:399\u2013409.","journal-title":"Nat Rev Rheumatol"},{"key":"980_CR19","doi-asserted-by":"publisher","first-page":"e16816","DOI":"10.1097\/MD.0000000000016816","volume":"98","author":"V Alende-Castro","year":"2019","unstructured":"Alende-Castro V, Alonso-Sampedro M, Vazquez-Temprano N, Tu\u00f1ez C, Rey D, Garc\u00eda-Iglesias C, et al. Factors influencing erythrocyte sedimentation rate in adults: new evidence for an old test. Medicine (Baltimore). 2019;98:e16816.","journal-title":"Medicine (Baltimore)"},{"key":"980_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.18773\/austprescr.2015.034","volume":"38","author":"M Harrison","year":"2015","unstructured":"Harrison M. Abnormal laboratory results: erythrocyte sedimentation rate and C-reactive protein. Aust Prescr. 2015;38:93\u20134.","journal-title":"Aust Prescr"},{"key":"980_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.smim.2018.09.003","volume":"40","author":"T Fulop","year":"2018","unstructured":"Fulop T, Witkowski JM, Olivieri F, Larbi A. The integration of inflammaging in age-related diseases. Semin Immunol. 2018;40:17\u201335.","journal-title":"Semin Immunol"},{"key":"980_CR22","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1136\/bmj.286.6361.266","volume":"286","author":"A Miller","year":"1983","unstructured":"Miller A, Green M, Robinson D. Simple rule for calculating normal erythrocyte sedimentation rate. BMJ. 1983;286:266.","journal-title":"BMJ."},{"key":"980_CR23","doi-asserted-by":"crossref","unstructured":"Cankurtaran M, Ulger Z, Halil M, Yavuz BB, Onal IK, Unal S, et al. How to assess high erythrocyte sedimentation rate (ESR) in elderly? Arch Gerontol Geriatr. 2010;50(3):323\u20136.","DOI":"10.1016\/j.archger.2009.05.008"},{"key":"980_CR24","doi-asserted-by":"crossref","unstructured":"Quinn KA, Gribbons KB, Carette S, Cuthbertson D, Khalidi NA, Koening CL. al. Patterns of clinical presentation in Takayasu\u2019s arteritis. Semin Arthritis Rheum WB Saunders. 2020;50:576\u201381. A prospective study on the different clinical patterns of TAK in one of the largest published cohorts.","DOI":"10.1016\/j.semarthrit.2020.04.012"},{"key":"980_CR25","doi-asserted-by":"crossref","unstructured":"Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 2010;33:1122\u20138.","DOI":"10.1002\/art.1780330810"},{"key":"980_CR26","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s10067-012-2031-3","volume":"31","author":"A Laria","year":"2012","unstructured":"Laria A, Zoli A, Bocci M, Castri F, Federico F, Ferraccioli GF. Systematic review of the literature and a case report informing biopsy-proven giant cell arteritis (GCA) with normal C-reactive protein. Clin Rheumatol. 2012;31:1389\u201393.","journal-title":"Clin Rheumatol"},{"key":"980_CR27","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1002\/art.39217","volume":"67","author":"L O\u2019Neill","year":"2015","unstructured":"O\u2019Neill L, Rooney P, Molloy D, Connolly M, McCormick J, McCarthy G, et al. Regulation of inflammation and angiogenesis in giant cell arteritis by acute-phase serum amyloid a. Arthritis Rheum. 2015;67:2447\u201356.","journal-title":"Arthritis Rheum"},{"key":"980_CR28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s10020-018-0047-0","volume":"24","author":"GH Sack","year":"2018","unstructured":"Sack GH. Serum amyloid a \u2013 a review. Mol Med. 2018;24:46.","journal-title":"Mol Med"},{"key":"980_CR29","doi-asserted-by":"crossref","unstructured":"Lv M, Xia Y, Li B, Liu H, Pan J, Li B, et al. Serum amyloid A stimulates vascular endothelial growth factor receptor 2 expression and angiogenesis. J Physiol Biochem. 2016;72:71\u201381.","DOI":"10.1007\/s13105-015-0462-4"},{"key":"980_CR30","doi-asserted-by":"crossref","unstructured":"Nair AM, Goel R, Hindhumati M, Jayakanthan K, Visalakshi J, Joseph G, et al. Serum amyloid A as a marker of disease activity and treatment response in Takayasu arteritis. Rheumatol Int Springer Verlag. 2017;37:1643\u20139.","DOI":"10.1007\/s00296-017-3786-2"},{"key":"980_CR31","doi-asserted-by":"crossref","unstructured":"Burja B, Feichtinger J, Lakota K, Thallinger GG, Sodin-Semrl S, Kuret T, et al. Utility of serological biomarkers for giant cell arteritis in a large cohort of treatment-na\u00efve patients. Clin Rheumatol. 2019;38:317\u201329.","DOI":"10.1007\/s10067-018-4240-x"},{"key":"980_CR32","doi-asserted-by":"publisher","first-page":"e3210","DOI":"10.1097\/MD.0000000000003210","volume":"95","author":"A Hocevar","year":"2016","unstructured":"Hocevar A, Rotar Z, Jese R, Semrl SS, Pizem J, Hawlina M, et al. Do early diagnosis and glucocorticoid treatment decrease the risk of permanent visual loss and early relapses in giant cell arteritis. Medicine (Baltimore). 2016;95:e3210.","journal-title":"Medicine (Baltimore)"},{"key":"980_CR33","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1161\/01.CIR.93.10.1788","volume":"93","author":"Y Seko","year":"1996","unstructured":"Seko Y, Sato O, Takagi A, Tada Y, Matsuo H, Yagita H, et al. Restricted usage of T-cell receptor Valpha-Vbeta genes in infiltrating cells in aortic tissue of patients with Takayasu\u2019s arteritis. Circulation. 1996;93:1788\u201390.","journal-title":"Circulation."},{"key":"980_CR34","doi-asserted-by":"crossref","unstructured":"Emilie D, Liozon E, Crevon M-C, Lavignac C, Portier A, Liozon F, et al. Production of interleukin 6 by granulomas of giant cell arteritis. Hum Immunol. 1994;39:17\u201324.","DOI":"10.1016\/0198-8859(94)90096-5"},{"key":"980_CR35","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/rheumatology\/kei266","volume":"45","author":"MC Park","year":"2006","unstructured":"Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu\u2019s arteritis. Rheumatology (Oxford). 2006;45:545\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"980_CR36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1161\/01.CIR.100.1.55","volume":"100","author":"M Noris","year":"1999","unstructured":"Noris M, Daina E, Gamba S, Bonazzola S, Remuzzi G. Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? Circulation. 1999;100:55\u201360.","journal-title":"Circulation."},{"key":"980_CR37","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/WNO.0b013e318268aa9b","volume":"32","author":"CM Weyand","year":"2012","unstructured":"Weyand CM, Liao YJ, Goronzy JJ. The immunopathology of giant cell arteritis: diagnostic and therapeutic implications. J Neuroophthalmol. 2012;32:259\u201365.","journal-title":"J Neuroophthalmol"},{"key":"980_CR38","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1186\/s13075-014-0479-z","volume":"16","author":"E Tombetti","year":"2014","unstructured":"Tombetti E, Di Chio MC, Sartorelli S, Papa M, Salerno A, Bottazzi B, et al. Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis. Arthritis Res Ther. 2014;16:479.","journal-title":"Arthritis Res Ther"},{"key":"980_CR39","doi-asserted-by":"crossref","unstructured":"Baldini M, Maugeri N, Ramirez GA, Giacomassi C, Castiglioni A, Prieto-Gonz\u00e1lez S, et al. Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: relevance for recent optic nerve ischemia. Arthritis Rheum. 2012;64:854\u201365.","DOI":"10.1002\/art.33411"},{"key":"980_CR40","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1365-2249.2009.03921.x","volume":"156","author":"N Maugeri","year":"2009","unstructured":"Maugeri N, Rovere-Querini P, Baldini M, Sabbadini MG, Manfredi AA. Translational mini-review series on immunology of vascular disease: mechanisms of vascular inflammation and remodelling in systemic vasculitis. Clin Exp Immunol. 2009;156:395\u2013404.","journal-title":"Clin Exp Immunol"},{"key":"980_CR41","doi-asserted-by":"crossref","unstructured":"Kotooka N, Inoue T, Fujimatsu D, Morooka T, Hashimoto S, Hikichi Y, et al. Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening. Atherosclerosis. 2008;197:368\u201374.","DOI":"10.1016\/j.atherosclerosis.2007.05.031"},{"key":"980_CR42","doi-asserted-by":"crossref","unstructured":"Maugeri N, Rovere-Querini P, Slavich M, Coppi G, Doni A, Bottazzi B, et al. Early and transient release of leukocyte pentraxin 3 during acute myocardial infarction. J Immunol. 2011;187:970\u20139.","DOI":"10.4049\/jimmunol.1100261"},{"key":"980_CR43","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1161\/CIRCULATIONAHA.107.749234","volume":"117","author":"M Salio","year":"2008","unstructured":"Salio M, Chimenti S, De Angelis N, Molla F, Maina V, Nebuloni M, et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2008;117:1055\u201364.","journal-title":"Circulation."},{"key":"980_CR44","doi-asserted-by":"crossref","unstructured":"Mutoh T, Shirai T, Ishii T, Shirota Y, Fujishima F, Takahashi F, et al. Identification of two major autoantigens negatively regulating endothelial activation in Takayasu arteritis. Nat Commun. 2020;11:1253.","DOI":"10.1038\/s41467-020-15088-0"},{"key":"980_CR45","doi-asserted-by":"crossref","unstructured":"Liozon E, Roblot P, Paire D, Loustaud V, Liozon F, Vidal E, et al. Anticardiolipin antibody levels predict flares and relapses in patients with giant-cell (temporal) arteritis. A longitudinal study of 58 biopsy-proven cases. Rheumatology. 2000;39:1089\u201394.","DOI":"10.1093\/rheumatology\/39.10.1089"},{"key":"980_CR46","first-page":"454","volume":"16","author":"G Nesher","year":"2014","unstructured":"Nesher G. Autoimmune aspects of giant cell arteritis. Isr Med Assoc J. 2014;16:454\u20135.","journal-title":"Isr Med Assoc J"},{"key":"980_CR47","doi-asserted-by":"crossref","unstructured":"Duhaut P, Berruyer M, Pinede L, Demolombe-Rague S, Loire R, Seydoux D, et al. Anticardiolipin antibodies and giant cell arteritis: a prospective, multicenter case-control study. Arthritis Rheum. 1998;41:701\u20139.","DOI":"10.1002\/1529-0131(199804)41:4<701::AID-ART18>3.0.CO;2-P"},{"key":"980_CR48","doi-asserted-by":"crossref","unstructured":"Espinosa G, T\u00e0ssies D, Font J, Mu\u00f1oz-Rodr\u00edguez FJ, Cervera R, Ordinas A, et al. Antiphospholipid antibodies and thrombophilic factors in giant cell arteritis. Semin Arthritis Rheum. 2001;31:12\u201320.","DOI":"10.1053\/sarh.2001.23499"},{"key":"980_CR49","first-page":"S711","volume":"65","author":"N Jordan","year":"2013","unstructured":"Jordan N, Bezanahary H, D\u2019Cruz DP. Clinical implications of antiphospholipid antibodies in Takayasu\u2019s arteritis. Arthritis Rheum. 2013;65:S711.","journal-title":"Arthritis Rheum"},{"key":"980_CR50","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1136\/annrheumdis-2011-200413","volume":"71","author":"NT Baerlecken","year":"2012","unstructured":"Baerlecken NT, Linnemann A, Gross WL, Moosig F, Vazquez-Rodriguez TR, Gonzalez-Gay MA, et al. Association of ferritin autoantibodies with giant cell arteritis\/polymyalgia rheumatica. Ann Rheum Dis. 2012;71:943\u20137.","journal-title":"Ann Rheum Dis"},{"key":"980_CR51","doi-asserted-by":"crossref","unstructured":"Gro\u00dfe K, Witte T, Moosig F, Hoyer BF, Lansche C, Schmidt RE, et al. Association of ferritin antibodies with Takayasu arteritis. Clin Rheumatol. 2014;33:1523\u20136.","DOI":"10.1007\/s10067-014-2764-2"},{"key":"980_CR52","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1136\/annrheumdis-2012-202963","volume":"72","author":"A Regent","year":"2013","unstructured":"Regent A, Ly KH, Blet A, Agard C, Puechal X, Tamas N, et al. Contribution of antiferritin antibodies to diagnosis of giant cell arteritis. Ann Rheum Dis. 2013;72:1269\u201370.","journal-title":"Ann Rheum Dis"},{"key":"980_CR53","doi-asserted-by":"publisher","first-page":"e002080","DOI":"10.1161\/CIRCGEN.117.002080","volume":"12","author":"X Cui","year":"2019","unstructured":"Cui X, Qin F, Song L, Wang T, Geng B, Zhang W, et al. Novel biomarkers for the precisive diagnosis and activity classification of Takayasu arteritis. Circ Genomic Precis Med NLM (Medline). 2019;12:e002080.","journal-title":"Circ Genomic Precis Med NLM (Medline)"},{"key":"980_CR54","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1002\/art.1780391019","volume":"39","author":"D Sorbi","year":"1996","unstructured":"Sorbi D, French DL, Nuovo GJ, Kew RR, Arbeit LA, Gruber BL. Elevated levels of 92-kd type IV collagenase (matrix metalloproteinase 9) in giant cell arteritis. Arthritis Rheum Wiley. 1996;39:1747\u201353.","journal-title":"Arthritis Rheum Wiley"},{"key":"980_CR55","doi-asserted-by":"crossref","unstructured":"van Sleen Y, Boots AMH, Abdulahad WH, Bijzet J, Sandovici M, van der Geest KSM, et al. High angiopoietin-2 levels associate with arterial inflammation and long-term glucocorticoid requirement in polymyalgia rheumatica. Rheumatology (Oxford). 2020;59:176\u201384. A prospective study on the role of angiogenesis markers in PMR-associated vasculitis.","DOI":"10.1093\/rheumatology\/kez261"},{"key":"980_CR56","doi-asserted-by":"crossref","unstructured":"Fukui S, Nunokawa T, Kobayashi S, Kamei S, Yokogawa N, Takizawa Y, et al. MMP-3 can distinguish isolated PMR from PMR with GCA: a retrospective study regarding PMR and GCA in Japan. Mod Rheumatol Taylor and Francis Ltd. 2016;26:259\u201364.","DOI":"10.3109\/14397595.2015.1071304"},{"key":"980_CR57","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s10067-015-2873-6","volume":"35","author":"X Wang","year":"2016","unstructured":"Wang X, Dang A, Lv N, Liu Q, Chen B. High-sensitivity C-reactive protein predicts adverse cardiovascular events in patients with Takayasu arteritis with coronary artery involvement. Clin Rheumatol Springer London. 2016;35:679\u201384.","journal-title":"Clin Rheumatol Springer London"},{"key":"980_CR58","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.3899\/jrheum.140113","volume":"41","author":"Q Liu","year":"2014","unstructured":"Liu Q, Dang A, Chen B, Lv N, Wang X, Zheng D. Function of N-terminal pro-brain natriuretic peptide in Takayasu arteritis disease monitoring. J Rheumatol. 2014;41:1683\u20138.","journal-title":"J Rheumatol"},{"key":"980_CR59","doi-asserted-by":"crossref","unstructured":"Martinez-Lado L, Calvi\u00f1o-D\u00edaz C, Pi\u00f1eiro A, Dierssen T, Vazquez-Rodriguez TR, Miranda-Filloy JA, et al. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine (Baltimore). 2011;90:186\u201393.","DOI":"10.1097\/MD.0b013e31821c4fad"},{"key":"980_CR60","doi-asserted-by":"crossref","unstructured":"Alba MA, Garc\u00eda-Mart\u00ednez A, Prieto-Gonz\u00e1lez S, Tavera-Bahillo I, Corbera-Bellalta M, Planas-Rigol E, et al. Relapses in patients with giant cell arteritis. Medicine (Baltimore). 2014;93:194\u2013201.","DOI":"10.1097\/MD.0000000000000033"},{"key":"980_CR61","first-page":"S30","volume":"26","author":"G Nesher","year":"2008","unstructured":"Nesher G, Nesher R, Mates M, Sonnenblick M, Breuer GS. Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease. Clin Exp Rheumatol. 2008;26:S30\u20134.","journal-title":"Clin Exp Rheumatol"},{"key":"980_CR62","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Rodr\u00edguez J, Garc\u00eda-Mart\u00ednez A, Casademont J, Filella X, Esteban MJ, L\u00f3pez-Soto A, et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum. 2002;47(1):29\u201335.","DOI":"10.1002\/art1.10161"},{"key":"980_CR63","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/1529-0131(199801)41:1<26::AID-ART4>3.0.CO;2-0","volume":"41","author":"MC Cid","year":"1998","unstructured":"Cid MC, Font C, Oristrell J, de la Sierra A, Coll-Vinent B, L\u00f3pez-Soto A, et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum. 1998;41:26\u201332.","journal-title":"Arthritis Rheum"},{"key":"980_CR64","doi-asserted-by":"crossref","unstructured":"Salvarani C, Cimino L, Macchioni P, Consonni D, Cantini F, Bajocchi G, et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum. 2005;53:293\u20137.","DOI":"10.1002\/art.21075"},{"key":"980_CR65","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Gay MA, Garc\u00eda-Porr\u00faa C, Llorca J, Hajeer AH, Bra\u00f1as F, Dababneh A, et al. Visual manifestations of giant cell arteritis: trends and clinical spectrum in 161 patients. Medicine (Baltimore). 2000;79:283\u201392.","DOI":"10.1097\/00005792-200009000-00001"},{"key":"980_CR66","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1161\/01.CIR.0000066907.83923.32","volume":"107","author":"J Hern\u00e1ndez-Rodr\u00edguez","year":"2003","unstructured":"Hern\u00e1ndez-Rodr\u00edguez J, Segarra M, Vilardell C, S\u00e1nchez M, Garc\u00eda-Mart\u00ednez A, Esteban M-J, et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation. 2003;107:2428\u201334.","journal-title":"Circulation."},{"key":"980_CR67","doi-asserted-by":"crossref","unstructured":"Lozano E, Segarra M, Corbera-Bellalta M, Garc\u00eda-Mart\u00ednez A, Esp\u00edgol-Frigol\u00e9 G, Pl\u00e0-Campo A, et al. Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: association between elevated plasma endothelin levels and the development of ischaemic events. Ann Rheum Dis. 2010;69:434\u201342.","DOI":"10.1136\/ard.2008.105692"},{"key":"980_CR68","doi-asserted-by":"crossref","unstructured":"Ramirez GA, Rovere-Querini P, Blasi M, Sartorelli S, Di Chio MC, Baldini M, et al. PTX3 intercepts vascular inflammation in systemic immune-mediated diseases. Front Immunol. Frontiers Media SA. 2019;10:1135. A prospective study on the relationship between pentraxin-3 and vascular inflammation in patients with different rheumatological diseases.","DOI":"10.3389\/fimmu.2019.01135"},{"key":"980_CR69","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1002\/1529-0131(200112)44:12<2841::AID-ART472>3.0.CO;2-6","volume":"44","author":"F Fazzini","year":"2001","unstructured":"Fazzini F, Peri G, Doni A, Dell\u2019Antonio G, Dal Cin E, Bozzolo E, et al. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum. 2001;44:2841\u201350.","journal-title":"Arthritis Rheum"},{"key":"980_CR70","unstructured":"Pulsatelli L, Peri G, Macchioni P, Boiardi L, Salvarani C, Cantini F, et al. Serum levels of long pentraxin PTX3 in patients with polymyalgia rheumatica. Clin Exp Rheumatol. 2010;28:756\u20138."},{"key":"980_CR71","doi-asserted-by":"crossref","unstructured":"Prieto-Gonz\u00e1lez S, Terrades-Garc\u00eda N, Corbera-Bellalta M, Planas-Rigol E, Miyabe C, Alba MA, et al. Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients. RMD Open. 2017;3:e000570. A prospective study on the role of osteopontin as a potential biomarker in GCA.","DOI":"10.1136\/rmdopen-2017-000570"},{"key":"980_CR72","doi-asserted-by":"crossref","unstructured":"van Sleen Y, Sandovici M, Abdulahad WH, Bijzet J, van der Geest KSM, Boots AMH, et al. Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis. Rheumatology. 2019;58:1383\u201392. A prospective study on the prognostic utility in GCA patients of different biomarkers, including IL-6, angiopoietins, calprotectin, and VEGF.","DOI":"10.1093\/rheumatology\/kez034"},{"key":"980_CR73","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1517\/21678707.2013.827570","volume":"1","author":"E Tombetti","year":"2013","unstructured":"Tombetti E, Manfredi A, Sabbadini MG, Baldissera E. Management options for Takayasu arteritis. Expert Opin Orphan Drugs. 2013;1:685\u201393.","journal-title":"Expert Opin Orphan Drugs"},{"key":"980_CR74","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5582\/irdr.3.29","volume":"3","author":"E Tombetti","year":"2014","unstructured":"Tombetti E, Di Chio MC, Sartorelli S, Bozzolo E, Sabbadini MG, Manfredi AA, et al. Anti-cytokine treatment for Takayasu arteritis: state of the art. Intractable Rare Dis Res. 2014;3:29\u201333.","journal-title":"Intractable Rare Dis Res"},{"key":"980_CR75","doi-asserted-by":"crossref","unstructured":"Tombetti E, Godi C, Ambrosi A, Doyle F, Jacobs A, Kiprianos AP, et al. Novel angiographic scores for evaluation of large vessel vasculitis. Sci Rep. 2018;8:15979.","DOI":"10.1038\/s41598-018-34395-7"},{"key":"980_CR76","doi-asserted-by":"crossref","unstructured":"Misra R, Danda D, Rajappa SM, Ghosh A, Gupta R, Mahendranath KM, et al. Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford). 2013;52:1795\u2013801.","DOI":"10.1093\/rheumatology\/ket128"},{"key":"980_CR77","doi-asserted-by":"publisher","first-page":"e3524","DOI":"10.1097\/MD.0000000000003524","volume":"95","author":"G Restuccia","year":"2016","unstructured":"Restuccia G, Boiardi L, Cavazza A, Catanoso M, Macchioni P, Muratore F, et al. Flares in biopsy-proven giant cell arteritis in northern Italy: characteristics and predictors in a long-term follow-up study. Medicine (Baltimore). 2016;95:e3524.","journal-title":"Medicine (Baltimore)"},{"key":"980_CR78","doi-asserted-by":"crossref","unstructured":"Kermani TA, Warrington KJ, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, et al. Disease relapses among patients with giant cell arteritis: a prospective, longitudinal cohort study. J Rheumatol. 2015;42:1213\u20137.","DOI":"10.3899\/jrheum.141347"},{"key":"980_CR79","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2217\/ijr.12.21","volume":"7","author":"A Makol","year":"2012","unstructured":"Makol A, Matteson EL. Utility of C-reactive protein in the diagnosis of giant cell arteritis: better than the erythrocyte sedimentation rate? Int J Clin Rheumtol. 2012;7:247\u201350.","journal-title":"Int J Clin Rheumtol"},{"key":"980_CR80","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jvs.2009.09.038","volume":"51","author":"J Ma","year":"2010","unstructured":"Ma J, Luo X, Wu Q, Chen Z, Kou L, Wang H. Circulation levels of acute phase proteins in patients with Takayasu arteritis. J Vasc Surg. 2010;51:700\u20136.","journal-title":"J Vasc Surg"},{"key":"980_CR81","doi-asserted-by":"crossref","unstructured":"Dartevel A, Toussaint B, Trocme C, Arnaud M, Simon N, Faure P, et al. Serum amyloid A as a marker of disease activity in Giant cell arteritis. Autoimmun Rev. 2020;19:102428.","DOI":"10.1016\/j.autrev.2019.102428"},{"key":"980_CR82","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/1529-0131(200005)43:5<1041::AID-ANR12>3.0.CO;2-7","volume":"43","author":"CM Weyand","year":"2000","unstructured":"Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum. 2000;43:1041\u20138.","journal-title":"Arthritis Rheum"},{"key":"980_CR83","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti\u2013IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112:3959\u201364.","journal-title":"Blood."},{"key":"980_CR84","doi-asserted-by":"crossref","unstructured":"Paccaly AJ, Kovalenko P, Parrino J, Boyapati A, Xu C, van Hoogstraten H, et al. Pharmacokinetics and pharmacodynamics of subcutaneous sarilumab and intravenous tocilizumab following single-dose administration in patients with active rheumatoid arthritis on stable methotrexate. J Clin Pharmacol. 2021;61(1):90\u2013104.","DOI":"10.1002\/jcph.1703"},{"key":"980_CR85","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1136\/annrheumdis-2018-214704","volume":"78","author":"CT Berger","year":"2019","unstructured":"Berger CT, Rebholz-Chaves B, Recher M, Manigold T, Daikeler T. Serial IL-6 measurements in patients with tocilizumab-treated large-vessel vasculitis detect infections and may predict early relapses. Ann Rheum Dis. 2019;78:1012\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"980_CR86","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.1016\/S0167-5273(98)00181-8","volume":"66","author":"GS Hoffman","year":"1998","unstructured":"Hoffman GS, Ahmed AE. Surrogate markers of disease activity in patients with Takayasu arteritis. A preliminary report from The International Network for the Study of the Systemic Vasculitides (INSSYS). Int J Cardiol. 1998;66(Suppl 1):S191\u20134 discussion S195.","journal-title":"Int J Cardiol"},{"issue":"Suppl 1","key":"980_CR87","first-page":"23","volume":"38","author":"L Pulsatelli","year":"2020","unstructured":"Pulsatelli L, Boiardi L, Assirelli E, Pazzola G, Muratore F, Addimanda O, et al. Imbalance between angiogenic and anti-angiogenic factors in sera from patients with large-vessel vasculitis. Clin Exp Rheumatol. 2020;38(Suppl 1):23\u201330.","journal-title":"Clin Exp Rheumatol"},{"key":"980_CR88","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2174\/1874312901711010023","volume":"11","author":"R Goel","year":"2017","unstructured":"Goel R, Kabeerdoss J, Ram B, Prakash JAJ, Babji S, Nair A, et al. Serum cytokine profile in Asian Indian patients with Takayasu arteritis and its association with disease activity. Open Rheumatol J. 2017;11:23\u20139.","journal-title":"Open Rheumatol J"},{"key":"980_CR89","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/acr.20043","volume":"62","author":"A Garc\u00eda-Mart\u00ednez","year":"2010","unstructured":"Garc\u00eda-Mart\u00ednez A, Hern\u00e1ndez-Rodr\u00edguez J, Esp\u00edgol-Frigol\u00e9 G, Prieto-Gonz\u00e1lez S, Butjosa M, Segarra M, et al. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor \u03b1 and interleukin-6) in the long-term followup of patients with giant cell arteritis. Arthritis Care Res. 2010;62:835\u201341.","journal-title":"Arthritis Care Res"},{"key":"980_CR90","doi-asserted-by":"crossref","unstructured":"Coll-Vinent B, Vilardell C, Font C, Oristrell J, Hernandez-Rodriguez J, Yague J, et al. Circulating soluble adhesion molecules in patients with giant cell arteritis. Correlation between soluble intercellular adhesion molecule-1 (sICAM-1) concentrations and disease activity. Ann Rheum Dis. 1999;58:189\u201392.","DOI":"10.1136\/ard.58.3.189"},{"key":"980_CR91","doi-asserted-by":"crossref","unstructured":"Visvanathan S, Rahman MU, Hoffman GS, Xu S, Garc\u00eda-Mart\u00ednez A, Segarra M, et al. Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis\u2013a prospective longitudinal study. Rheumatology (Oxford). 2011;50:2061\u201370. A sub-analysis from an RCT of infliximab inGCA, including baseline and follow-up temporal artery biopsies.","DOI":"10.1093\/rheumatology\/ker163"},{"key":"980_CR92","doi-asserted-by":"crossref","unstructured":"Rodriguez-Pla A, Warner RL, Cuthbertson D, Carette S, Khalidi NA, Koening CL, et al. Evaluation of potential serum biomarkers of disease activity in diverse forms of vasculitis. J Rheumatol. 2020;47:1001\u201310.","DOI":"10.3899\/jrheum.190093"},{"key":"980_CR93","doi-asserted-by":"crossref","unstructured":"Saadoun D, Garrido M, Comarmond C, Desbois AC, Domont F, Savey L, et al. Th1 and Th17 cytokines drive inflammation in Takayasu arteritis. Arthritis Rheum. 2015;67:1353\u201360.","DOI":"10.1002\/art.39037"},{"key":"980_CR94","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1161\/CIRCULATIONAHA.109.872903","volume":"121","author":"J Deng","year":"2010","unstructured":"Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation. 2010;121:906\u201315.","journal-title":"Circulation"},{"key":"980_CR95","first-page":"304","volume":"21","author":"K Matsumoto","year":"2019","unstructured":"Matsumoto K, Suzuki K, Yoshimoto K, Seki N, Tsujimoto H, Chiba K, et al. Significant association between clinical characteristics and changes in peripheral immuno-phenotype in large vessel vasculitis. Arthritis Res Ther. BioMed Central Ltd. 2019;21:304.","journal-title":"BioMed Central Ltd"},{"key":"980_CR96","first-page":"S10","volume":"24","author":"M-C Park","year":"2006","unstructured":"Park M-C, Park Y-B, Jung SY, Lee KH, Lee S-K. Anti-endothelial cell antibodies and antiphospholipid antibodies in Takayasu\u2019s arteritis: correlations of their titers and isotype distributions with disease activity. Clin Exp Rheumatol. 2006;24:S10\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"980_CR97","first-page":"2","volume":"28","author":"Y Nishino","year":"2010","unstructured":"Nishino Y, Tamai M, Kawakami A, Koga T, Makiyama J, Maeda Y, et al. Serum levels of BAFF for assessing the disease activity of Takayasu arteritis. Clin Exp Rheumatol Clin Exp Rheumatol. 2010;28:2\u20135.","journal-title":"Clin Exp Rheumatol Clin Exp Rheumatol"},{"key":"980_CR98","doi-asserted-by":"crossref","unstructured":"Zanwar A, Jain A, Gupta L, Chaurasia S, Kumar S, Misra DP, et al. Serum BAFF and APRIL levels in Indian patients with Takayasu arteritis. Clin Rheumatol Springer London. 2018;37:3439\u201342.","DOI":"10.1007\/s10067-018-4207-y"},{"key":"980_CR99","doi-asserted-by":"crossref","unstructured":"van der Geest KSM, Abdulahad WH, Chalan P, Rutgers A, Horst G, Huitema MG, et al. Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2014;66:1927\u201338.","DOI":"10.1002\/art.38625"},{"key":"980_CR100","doi-asserted-by":"crossref","unstructured":"Sun Y, Kong X, Wu S, Ma L, Yan Y, Lv P, et al. YKL-40 as a new biomarker of disease activity in Takayasu arteritis. Int J Cardiol Elsevier Ireland Ltd. 2019;293:231\u20137. A prospective study comparing different biomarkers in patients with active versus inactive TAK.","DOI":"10.1016\/j.ijcard.2019.06.058"},{"key":"980_CR101","doi-asserted-by":"crossref","unstructured":"Kunz LIZ, van\u2019t Wout EFA, van Schadewijk A, Postma DS, Kerstjens HAM, Sterk PJ, et al. Regulation of YKL-40 expression by corticosteroids: effect on pro-inflammatory macrophages in vitro and its modulation in COPD in vivo. Respir Res. 2015;16:154.","DOI":"10.1186\/s12931-015-0314-3"},{"key":"980_CR102","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41584-018-0058-9","volume":"14","author":"J Austermann","year":"2018","unstructured":"Austermann J, Spiekermann C, Roth J. S100 proteins in rheumatic diseases. Nat Rev Rheumatol. 2018;14:528\u201341.","journal-title":"Nat Rev Rheumatol"},{"key":"980_CR103","doi-asserted-by":"crossref","first-page":"245","DOI":"10.33549\/physiolres.930448","volume":"53","author":"I Str\u00edz","year":"2004","unstructured":"Str\u00edz I, Trebichavsk\u00fd I. Calprotectin - a pleiotropic molecule in acute and chronic inflammation. Physiol Res. 2004;53:245\u201353.","journal-title":"Physiol Res"},{"key":"980_CR104","doi-asserted-by":"crossref","unstructured":"Springer JM, Monach P, Cuthbertson D, Carette S, Khalidi NA, McAlear CA, et al. Serum S100 proteins as a marker of disease activity in large vessel vasculitis. J Clin Rheumatol. 2018;24:393\u20135. A prospective study on the relationship between S100 proteins and disease activity in patients with GCA and TAK.","DOI":"10.1097\/RHU.0000000000000729"},{"key":"980_CR105","doi-asserted-by":"crossref","unstructured":"Goel R, Nair A, Kabeerdoss J, Mohan H, Jeyaseelan V, Joseph G, et al. Study of serial serum myeloid-related protein 8\/14 as a sensitive biomarker in Takayasu arteritis: a single centre study. Rheumatol Int Springer Verlag. 2018;38:623\u201330.","DOI":"10.1007\/s00296-017-3881-4"},{"key":"980_CR106","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s42358-018-0025-9","volume":"58","author":"LSG Machado","year":"2018","unstructured":"Machado LSG, Oliveira ACD, Semedo-Kuriki P, de Souza AWS, Sato EI. Endothelial progenitor cells and vascular endothelial growth factor in patients with Takayasu\u2019s arteritis. Adv Rheumatol NLM (Medline). 2018;58:24.","journal-title":"Adv Rheumatol NLM (Medline)"},{"key":"980_CR107","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13075-016-1082-2","volume":"18","author":"E Tombetti","year":"2016","unstructured":"Tombetti E, Colombo B, Di Chio MC, Sartorelli S, Papa M, Salerno A, et al. Chromogranin-A production and fragmentation in patients with Takayasu arteritis. Arthritis Res Ther. 2016;18:187.","journal-title":"Arthritis Res Ther"},{"key":"980_CR108","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1161\/01.RES.0000040420.17366.2E","volume":"91","author":"A Cho","year":"2002","unstructured":"Cho A, Reidy MA. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res. 2002;91:845\u201351.","journal-title":"Circ Res"},{"key":"980_CR109","doi-asserted-by":"crossref","unstructured":"Dogan S, Piskin O, Solmaz D, Akar S, Gulcu A, Yuksel F, et al. Markers of endothelial damage and repair in Takayasu arteritis: are they associated with disease activity? Rheumatol Int. 2014;34:1129\u201338.","DOI":"10.1007\/s00296-013-2937-3"},{"key":"980_CR110","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000453038","volume":"26","author":"\u015e\u00d6 Ke\u015fkek","year":"2017","unstructured":"Ke\u015fkek \u015e\u00d6, Bozklrll-Ers\u00f6zl\u00fc ED, Kozanoglu I, Y\u00fccel AE. High levels of circulating endothelial progenitor cells are associated with acrotism in patients with Takayasu arteritis. Med Princ Pract S Karger AG. 2017;26:132\u20138.","journal-title":"Med Princ Pract S Karger AG"},{"key":"980_CR111","doi-asserted-by":"crossref","unstructured":"Gloor AD, Yerly D, Adler S, Reichenbach S, Kuchen S, Seitz M, et al. Immuno-monitoring reveals an extended subclinical disease activity in tocilizumab-treated giant cell arteritis. Rheumatology. 2018;57:1795\u2013801.","DOI":"10.1093\/rheumatology\/key158"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-021-00980-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-021-00980-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-021-00980-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T01:02:07Z","timestamp":1697850127000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-021-00980-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,10]]},"references-count":111,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["980"],"URL":"https:\/\/doi.org\/10.1007\/s11926-021-00980-5","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,10]]},"assertion":[{"value":"5 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"17"}}